Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[11C]-Lu AF90103 BBB Penetration in Healthy Men
NCT05306366Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lu AF90103 in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoints: Area Under the Time-Activity Curves for Brain, Area Under the Blood Concentrations Over Time and 4 more. Started Mar 2022; status: completed.
02
Drugs
Lu AF90103
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05306366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306366.